Direct antithrombin agents ameliorate disseminated intravascular coagulation in suspected heparin-induced thrombocytopenia thrombosis syndrome

Clinical and Applied Thrombosis/Hemostasis

Volumn 8, Issue 3, 2002, Pages 287-289

  Mukundan, S ^a   Zeigler, Z R ^a,b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b West Penn Allegheny Health System   (Japan)

Author keywords

Direct antithrombins; Disseminated intravascular coagulation

Indexed keywords

ANTITHROMBIN; ARGATROBAN; HEPARIN; LEPIRUDIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE COURSE; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA THROMBOSIS SYNDROME; HUMAN; MALE; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME;

EID: 0036657771     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960200800314     Document Type: Article

References (11)

1. Greinacher A, Janssens U, Berg G, et al. Lepirudin [recombinant hirudin] for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study [HAT] investigators. Circulation 1999;100:587.
2. Greinacher A, Volpel H, Janssens U, et al. Recombinant hirudin [lepirudin] provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study. Circulation 1999;99:73.
3. Lewis BE, Walenga JM, Wallis DE. Anticoagulation with Novastan [argatroban] in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Semin Thromb Hemost 1997;23:197.
4. Ortel TL, Chong BH. New treatment options for heparin-induced thrombocytopenia. Semin Hematol 1998;35:26.
5. Hauptmann J, Bruggener E, Marwardt F. Effect of heparin, hirudin, and a synthetic thrombin inhibitor on antithrombin III in thrombin-induced disseminated intravascular coagulation in rats. Haemostasis 1987;17:321.
6. Hermida J, Montes R, Parmo JA, Rocha E. Endotoxin-induced disseminated intravascular coagulation in rabbits: Effect of recombinant hirudin on hemostatic parameters, fibrin deposits, and mortality. J Lab Clin Med 1998;131:77.
7. Krupinski K, Breddin HK, Markward F, Haarmann W. Antithrombotic effects of three thrombin inhibitors in a rat model of laser-induced thrombosis. Haemostasis 1989;19:74.
8. Higuchi M, Kunitomi O, Nishida Y, et al. [Effect of MD-805, a synthetic thrombin inhibitor on disseminated intravascular coagulation developing in hematological disorders]. Rinsho Ketsueki 1985;26:1754.
9. Kumon Y, Tanaka K, Nakjima N, et al. Anticoagulation with a synthetic thrombin inhibitor after cardiovascular surgery and for treatment of disseminated intravascular coagulation. Crit Care Med 1984;12:1039.
10. Saito M, Asakura H, Jakaji H, et al. Recombinant hirudin for the treatment of disseminated intravascular coagulation in patients with haematological malignancy. Blood Coagul Fibrinolysis 1995;6:60.
11. Yamada K. A clinical trial of MD-805, a synthetic thrombin inhibitor, for the treatment of DIC. Bibl Haematol 1983;49:343.